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Sirtuins are protein deacetylases regulating aging
processes and various physiological functions. Re-
sveratrol, a polyphenol found in red wine, activates
human Sirt1 and inhibits Sirt3, and it can mimic calo-
rie restriction effects, such as lifespan extension in
lower organisms. The mechanism of Sirtuin modula-
tion by resveratrol is not well understood. We used
40-bromo-resveratrol (5-(2-(4-hydroxyphenyl)vinyl)-
1,3-benzenediol) to study Sirt1 and Sirt3 modulation.
Despite its similarity to the Sirt1 activator resveratrol,
the compound potently inhibited both, Sirt1 and
Sirt3. Crystal structures of Sirt3 in complex with a
fluorophore-labeled and with a native substrate
peptide, respectively, in presence of 40-bromo-
resveratrol reveal two compound binding sites.
Biochemical studies identify the internal site and
substrate competition as the mechanism for inhibi-
tion, providing a drug target site, and homology
modeling suggests that the second, allosteric site
might indicate the site for Sirt1 activation.
INTRODUCTION
Sirtuins are NAD+-dependent protein deacetylases conserved
throughout evolution. They deacetylate various targets and
thereby control cellular processes ranging from genomic integ-
rity to stress responses and metabolism (Haigis and Sinclair,
2010; Michan and Sinclair, 2007). In mammals, there are seven
Sirtuin isoforms, Sirt1–7, that differ in their cellular localization
and function (Haigis and Sinclair, 2010; Michan and Sinclair,
2007). The nuclear Sirtuins Sirt1, 6, and 7 deacetylate proteins
contributing to DNA maintenance and transcription such as
Ku70 and p53 (Haigis and Sinclair, 2010). The mainly cytosolic
Sirt2 regulates, for example, tubulin polymerization (North
et al., 2003). Among the mitochondrial isoforms Sirt3, 4, and 5,
Sirt3 appears to be the major deacetylase and a key regulator
of metabolism especially for adaption to limited nutrient supply
(Newman et al., 2012). Consistently, Sirt3 regulates substrates
involved, for example, in ATP production, fatty acid oxidation,
and the citric acid cycle but also inmitochondrial integrity, oxida-Chemistry & Biology 20, 1375–138tive stress responses, and apoptosis (Hebert et al., 2013; Verdin
et al., 2010). Sirt4 influences fatty acid metabolism through de-
acetylation of malonyl-CoA decarboxylase (Laurent et al.,
2013), and strong evidence links this isoform to insulin secretion
(Haigis et al., 2006). Sirt5 was recently described to more effi-
ciently demalonylate or desuccinylate its substrates (Du et al.,
2011) and it was reported to regulate the urea cycle through its
target carbamoyl phosphate synthetase 1 (CPS1; Gertz and
Steegborn, 2010; Nakagawa et al., 2009).
Sirtuins share a highly conserved catalytic core but differ in N-
and C-terminal extensions (Frye, 2000; Sanders et al., 2010). The
catalytic core consists of two domains (Sanders et al., 2010;
Sauve et al., 2006), a larger Rossmann-fold domain typical for
NAD+ binding proteins and a smaller, more variable zinc-binding
domain. The zinc ion is coordinated by four invariant cysteines
and appears essential for the stability of the protein (Sauve
et al., 2006). The acetylated substrate and the NAD+ cosubstrate
bind in a cleft between the two domains thereby inducing closure
of the active site (Jin et al., 2009) and stabilization of a so-called
cofactor binding loop (Sanders et al., 2010). In a productive
conformation, the nicotinamide moiety of NAD+ is buried in the
highly conserved C pocket (Hoff et al., 2006). Thereby, the glyco-
sidic bond to the nicotinamide ribose is stretched, which facili-
tates nicotinamide release and alkylamide formation between
acetyl-Lys and the ADP-ribose 10-C position (Sauve and Youn,
2012). Hydrolysis of the alkylimidate leads to the products, de-
acetylated protein and 20-O-acetyl-ADP-ribose (OAADPr) (Sauve
and Youn, 2012).
Sirtuins contribute to the regulation of aging processes and
aging-related diseases, such as neurological disorders or meta-
bolic syndrome (Rahman and Islam, 2011), and they were shown
to mediate lifespan-extending effects of caloric restriction (CR;
Cohen et al., 2004; Guarente, 2005; Guarente and Picard,
2005). Thus, they are considered attractive drug targets. Exten-
sive efforts to develop Sirtuin inhibitors and activators (Chen,
2011; Villalba and Alcaı´n, 2012), however, yielded few promising
compounds, such as the potent and mildly Sirt1-specific inhibi-
tor Ex-527 (Napper et al., 2005). Most other Sirtuin modulators
suffer from low potency and/or specificity, and mechanistic in-
vestigations are needed for their improvement. The polyphenol
resveratrol (3,5,40-trihydroxy-trans-stilbene; Figure 1A) was
shown to activate Sirt1 and to induce Sirtuin mediated life-
span-extension similar to CR (Howitz et al., 2003). However, re-
sveratrol shows low potency against Sirt1 and affects several
cellular targets (Park et al., 2012; Pirola and Fro¨jdo¨, 2008). In5, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1375
Figure 1. 40-Bromo-Resveratrol Is a Potent
hSirt3 Inhibitor
(A) Chemical structures of resveratrol (3,5,40-trihy-
droxy-trans-stilbene) and its related compounds
40-bromo-resveratrol (5-(2-(4-hydroxyphenyl)vi-
nyl)-1,3-benzenediol), polydatin (reservatrol-3-
b-D-glucoside), and piceatannol (3,5,30,40-tetra-
hydroxy-trans-stilbene).
(B) Inhibition of hSirt3 by resveratrol-related com-
pounds in the FdL assay at 0.2 mM and 1 mM
compound concentrations. Activities are normal-
ized to the control in the absence of compounds.
Error bars: SD from two independent measure-
ments. RESV, resveratrol; brRESV, 40-bromor-
esveratrol; PCT, piceatannol; PD, polydatin.
(C) Resveratrol (0.2 mM) activates hSirt1 in the FdL
assay, whereas 40-bromo-resveratrol inhibits.
Activities were normalized to the control in
absence of compound. Error bars: SD from two
independent measurements.
(D) Up to 0.2 mM 40-bromo-resveratrol inhibit the
Sirt5 desuccinylase activity against succinylated
FdL substrate only weakly. Activities were
normalized to the control in absence of compound.
Error bars: SD from two independent measure-
ments.
(E) IC50 determination of 4
0-bromo-resveratrol on
hSirt3 against 500 mM ACS2 peptide using MS.
Error bars: SE of linear fits to time series experi-
ments.
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Sirt3 Inhibition by 40-Bromo-Resveratrolfact, we recently showed that resveratrol can also activate Sirt5
and inhibit Sirt3 (Gertz et al., 2012). Crystal structures revealed
that the modulating effect of resveratrol and its analog piceatan-
nol (3,5,30,40-tetrahydroxy-trans-stilbene; Figure 1A) is based on
a direct interaction with the substrate in case of the fluorophor-
labeled Fluor-de-Lys (FdL) peptide used in that study.
We used 40-bromo-resveratrol (5-(2-(4-hydroxyphenyl)vinyl)-
1,3-benzenediol; Figure 1A) as a tool for crystallographic studies
with fluorophore-free substrate peptide. Interestingly, the bromo
group dramatically increases the compound’s potency on hu-
man Sirt3 (hSirt3) and it also inhibits, rather than activates, hSirt1.
Crystal structures of hSirt3 in complex with peptide and
40-bromo-resveratrol reveal two binding sites for this compound1376 Chemistry & Biology 20, 1375–1385, November 21, 2013 ª2013 Elsevier Ltd All rights rescaffold. Binding analyses and enzyme
kinetics reveal inhibition site and mecha-
nism, and our data further suggest a
potential resveratrol binding site for
hSirt1 activation.
RESULTS
40-Bromo-Resveratrol Is a Potent
hSirt3 Inhibitor
We previously found that the hSirt1 acti-
vator resveratrol also affects hSirt3 and
hSirt5 activity (Gertz et al., 2012), but
the compound shows a low potency
against all Sirtuins. We therefore tested
40-bromo-resveratrol effects on Sirtuins
to identify a resveratrol derivative thatshows higher solubility and can be unequivocally located in crys-
tal structures based on the halogen’s anomalous signal. Testing
resveratrol and its analogs piceatannol, polydatin (reservatrol-3-
b-D-glucoside), and 40-bromo-resveratrol (Figure 1A) against
hSirt3 in the FdL assay confirmed the weak inhibition by resver-
atrol and piceatannol (Gertz et al., 2012) and showed an even
weaker effect for polydatin (Figure 1B). Surprisingly, 40-bromo-
resveratrol showed a much more potent effect and inhibited
hSirt3 activity almost completely at 0.2 mM compound concen-
tration (Figure 1B). Interestingly, we found the same, inhibitory
effect of 0.2 mM 40-bromo-resveratrol on hSirt1, in contrast to
the 17-fold activation by 0.2 mM resveratrol (Figure 1C). In
contrast to its effect on Sirt1 and Sirt3, 40-bromo-resveratrolserved
Figure 2. Crystal Structure of hSirt3 in Com-
plex with 40-Bromo-Resveratrol and FdL-1
Peptide
(A) Overall structure of hSirt3/FdL-1/40-bromo-re-
sveratrol complex. The dashed line indicates a
loop not defined by electron density.
(B) FdL-1 peptide and 40-bromo-resveratrol
ligands of hSirt3, overlaid with omit Fo-Fc differ-
ence density (2.5s; green) and anomalous density
(5s; magenta) showing the positions of Br and
Zn2+. See Figure S1 for anomalous density con-
toured at various s levels.
(C) hSirt3/FdL-1/40-bromo-resveratrol complex
structure with 2Fo-Fc density for the ligands con-
toured at 1s.
(D) Closer view on the 40-bromo-resveratrol bind-
ing site showing interacting residues. Hydrogen
bonds are indicated by dashed lines.
(E) Superposition of the hSirt3/FdL-1/40-bromo-
resveratrol structure with a hSirt3/ACS2/carba-
NAD+ complex (PDB ID 4FVT; Szczepankiewicz
et al., 2012). FdL-1 peptide and 40-bromo-resver-
atrol are shown in pink, p53 peptide and NAD+ in
green. The protein part of the hSirt3/ACS2/carba-
NAD+ complex is omitted for clarity.
(F) Superposition of the hSirt3/FdL-1/40-bromo-
resveratrol (pink) with the hSirt3/FdL-1/PCT com-
plex (yellow, PDB ID 4HD8; Gertz et al., 2012).
FdL-1 peptide and 40-bromo-resveratrol are
shown in pink, FdL-1 peptide and PCT in yellow.
(A, B, and E) The missing loop is indicated by a
dashed line. bRESV, 40-bromo-resveratrol; PCT,
piceatannol.
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Sirt3 Inhibition by 40-Bromo-Resveratrolinhibited the desuccinylation activity of Sirt5 only weakly (Fig-
ure 1D). This partial selectivity and the increased potency against
hSirt1 and hSirt3 suggest that this compound scaffold and its
binding site bear potential for the development of isoform-
selective Sirtuin inhibitors.
The FdL substrate peptide carries a fluorophor that can
interact with small molecules, potentially leading to artificial ef-
fects on Sirtuin activity (Borra et al., 2004; Gertz et al., 2012; Pa-
cholec et al., 2010). We therefore used a mass spectrometry
(MS)-based assay and a fluorophore-free acetylated peptide
derived from the physiological Sirt3 target acetyl-CoA synthe-
tase 2 (ACS2) as a substrate to confirm and quantify hSirt3 inhi-
bition by 40-bromo-resveratrol. A dose-response experiment at
500 mM ACS2 peptide concentration yielded an half-maximal
inhibitory concentration (IC50) value of 143.0 ± 3.6 mM (Figure 1E).
This result confirms that inhibition by 40-bromo-resveratrol ap-
plies to fluorophore-free peptides and the lower potency in this
assay, performed at higher peptide concentration, might indi-
cate competition with this substrate (see also below).Chemistry & Biology 20, 1375–1385, November 21, 2013 ªCrystal Structure of hSirt3
in Complex with 40-Bromo-
Resveratrol and FdL-1 Peptide
To identify binding site and inhibition
mechanism of 40-bromo-resveratrol, we
first co-crystallized hSirt3 and compound
in the presence of FdL-1 peptide. In the
resulting hSirt3/FdL-1/40-bromo-resvera-
trol complex structure, the compound was found in the active
site (Figures 2A–2C; Table 1). Significant Fo-Fc omit density (Fig-
ure 2B) indicated compound position and orientation, which was
confirmed by a strong anomalous signal for the inhibitor’s 40-
bromo atom (Figure 2B; Figure S1 available online), and complex
refinement resulted in excellent 2Fo-Fc density for the ligand (Fig-
ure 2C). Interestingly, the inhibitor is arranged differently from the
weaker inhibitor piceatannol in the previously solved hSirt3/FdL-
1/piceatannol complex (Gertz et al., 2012; see below). A closer
look at the compound binding site (Figure 2D) shows that the
A-ring hydroxyl groups of 40-bromo-resveratrol form hydrogen
bonds with Asn229 and Asp231 of hSirt3. Furthermore, residues
Ile230, Leu199, and Ile154 form a hydrophobic patch for A-ring
binding, and Phe157, Leu195, and Phe180 a hydrophobic cleft
for accommodating the B-ring. This cleft extends in a hydropho-
bic pocket (formed by Ile179, Leu173, and Tyr171) for binding
the bromine atom, and Arg158 and Pro176 form a lid shielding
this pocket from solvent. Superposition of the hSirt3/FdL-1/40-
bromo-resveratrol complex with a structure of hSirt3 in complex2013 Elsevier Ltd All rights reserved 1377
Table 1. Data Collection and Refinement Statistics
hSirt3/FdL-1/
40-Bromo-Resveratrol
hSirt3/ACS2/
40-Bromo-Resveratrol
Space group R32 P21212
Unit cell constants (A˚) a = b = 114.8,
c = 123.7
a = 52.6, b = 159.7,
c = 34.7
Resolution (A˚) 46.1–2.1 46.1–2.0
Unique reflections 18,510 20,570
<I/s> (outermost shell) 18.4 (2.8) 14.9 (2.8)
Completeness
(outermost shell) (%)
100.0% (100.0) 99.6% (100.0)
Rmerge (outermost
shell) (%)a
8.5 (78.0) 5.9 (50.2)
Rmeas (outermost
shell) (%)b
9.1 (83.6) 6.8 (58.3)
Resolution range for
refinement (A˚)
46.1–2.1 46.1–2.0
Total number of
reflections used
17,585 19,507
Number of atoms in asymmetric unit
Protein 2,064 2,057
Ligands 95 79
Water 136 125
Rmsds
Bond length (A˚) 0.02 0.02
Bond angles () 2.2 1.9
Average B factor (A˚2)
Protein 38.5 39.9
Peptide 42.9 43.1
40-bromo-resveratrol 66.5 68.5
Zinc ions 24.0 24.9
Final Rcryst/Rfree (%)
c,d 18.3/24.0 19.4/24.1
aRmerge =
PðI hIiÞP
I
. I is the intensity of an individual measurement and hIi
the corresponding mean value.
bRmeas =
P
h
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
nh
nh  1
r Pnh
i
jbIhIh;ij
P
h
Pnh
i
Ih;i
with bIh = 1
nh
Xnh
i
Ih;i.
cR-factor =
PjjFobsj  kjFcalcjjPjFobsj ; jFobsj is the observed and jFcalcj the
calculated structure factor amplitude.
dRfree was calculated from 5% of measured reflections omitted from
refinement.
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Sirt3 Inhibition by 40-Bromo-Resveratrolwith ACS2 peptide and the NAD+ analog carba-NAD+ (Szcze-
pankiewicz et al., 2012) reveals that 40-bromo-resveratrol
occupies part of the NAD+ binding pocket, in particular the
C-pocket (Figure 2E). This arrangement prevents the insertion
of the NAD+ nicotinamide moiety in the C-pocket necessary for
catalysis, which indicates competitive inhibition with respect to
this cosubstrate.
The overall hSirt3 and FdL1-peptide conformations in the
superposition of the 40-bromo-resveratrol complex with hSirt3
bound to FdL-1 and another resveratrol-related compound,
piceatannol, are identical (Figure 2F), although the inhibition
mechanisms of these compounds appear to be different.1378 Chemistry & Biology 20, 1375–1385, November 21, 2013 ª2013Piceatannol interacts extensively with the FdL-1 fluorophore,
apparently causing nonproductive peptide binding (Gertz
et al., 2012), while 40-bromo-resveratrol does not directly
contact this substrate peptide and blocks productive NAD+
binding.
Crystal Structure of hSirt3 in Complex with ACS2
Substrate Peptide and 40-Bromo-Resveratrol
Crystallizing hSirt3 in complex with ACS2 peptide, instead of
FdL-1 peptide, in presence of 40-bromo-resveratrol resulted in
a different hSirt3/peptide/inhibitor arrangement. The compound
molecule was found at the bottom of the Rossmann-fold domain,
interacting with Arg139, Met331, and Arg335, rather than in the
catalytic pocket (Figures 3A and 3B; Figure S2; Table 1). In this
exposed position, the compound interacts only through its
A-ring with this shallow hSirt3 pocket, and the bromo-containing
aromatic ring points toward the symmetry-related monomer in
the crystal lattice.
Superposition of the hSirt3/40-bromo-resveratrol complexes
with FdL-1 and ACS2 peptide, respectively, reveals that the in-
hibitor cannot bind at the catalytic pocket when the ACS2 pep-
tide is bound, since it would clash with the C-terminal part of
this substrate peptide (Figure 3C). The obtained hSirt3/ACS2/
40-bromo-resveratrol complex can either show a different com-
pound site and mechanism for 40-bromo-resveratrol inhibition
than the FdL-1 complex, or this second site is a crystallization
artifact and the inhibitory site simply not occupied due to compe-
tition with the highly concentrated ACS2 peptide. In fact,
40-bromo-resveratrol in the complex structure with hSirt3/
ACS2-peptide does not show many interactions with hSirt3,
rendering it a less likely inhibition site. Figure 3D illustrates the
hydrogen bonds of 40-bromo-resveratrol with Arg139, Met331
(backbone), Arg335, and Arg384 of the symmetry-related mono-
mer, and the very limited interaction interface with the hSirt3
monomer (see also Figure 3A).
To test whether the surface site occupied by 40-bromo-re-
sveratrol in its hSirt3/ACS2 complex is relevant for inhibition,
the role of the interacting residues R139, M331, R335, and
R384 were tested by site-directed mutagenesis to alanine.
Microscale thermophoresis (MST) results indicated that the
hSirt3-R335A variant might have a slightly reduced binding af-
finity for the compound compared to wild-type hSirt3 (Figure 3E),
but the change was not statistically significant. The hSirt3 vari-
ants R384A, R139A, and M331A showed no change in the affin-
ity for the compound. Moreover, we performed activity assays
with 500 mM ACS2 as peptide substrate and in presence of
40-bromo-resveratrol (at its IC50, 140 mM) to examine the effects
on the activity of the mutant proteins. The screening indicated
that the activity of hSirt3-R335A is slightly higher than that for
the other mutants and the wild-type protein (data not shown).
An IC50 determination for 4
0-bromo-resveratrol inhibition of
hSirt3-R335A activity showed only a small shift of the inhibition
curve compared to wild-type protein (Figure 3F), yielding IC50
values of 143.0 ± 3.6 (wild-type) and 179.2 ± 12.3 mM (hSirt3-
R335A), respectively. Therefore, the position of 40-bromo-
resveratrol in the complex structure hSirt3-ACS2-40-bromo-
resveratrol appears to slightly influence activity but seems not
to be primarily responsible for the inhibitory effect of the com-
pound on hSirt3.Elsevier Ltd All rights reserved
Figure 3. Crystal Structure of hSirt3 in
Complex with ACS2 Substrate Peptide and
Analysis of the Role of the Allosteric
40-Bromo-Resveratrol Site
(A) Overall structure of hSirt3/ACS2/40-bromo-re-
sveratrol complex. Amissing loop is indicated by a
dashed line.
(B) 40-bromo-resveratrol ligandof the hSirt3/ACS2/
40-bromo-resveratrol complex, overlaid with omit
Fo-Fc difference density (2.5s; green) and anoma-
lous density (5s; magenta) showing the position
of Br and surrounding residues important for
compound binding. Residues from the symmetry-
related monomer are labeled with a star. See
Figure S2 for 2Fo-Fc density for peptide and
inhibitor.
(C) Superposition of the hSirt3/ACS2/40-bromo-
resveratrol structure with the hSirt3/FdL-1/40-
bromo-resveratrol complex. FdL-1 peptide and
40-bromo-resveratrol are shown in pink, ACS2
peptide in cyan. Phe157 of the hSirt3/ACS2/40-
bromo-resveratrol and hSirt3/FdL-1/40-bromo-
resveratrol complex are shown in cyan and pink,
respectively.
(D) Closer view on the 40-bromo-resveratrol bind-
ing site in the hSirt3/ACS2/40-bromo-resveratrol
complex showing interacting residues. Hydrogen
bonds are indicated by dashed lines and residues
of the next symmetry-relatedmonomer are labeled
with a star.
(E) Affinity measurements for binding of 40-bromo-
resveratrol to hSirt3wild-typeaswell asR335Aand
R384A variants. Error bars: SD from two indepen-
dent measurements.
(F) IC50 determination of 4
0-bromo-resveratrol on
wild-type hSirt3 or the R335A variant against
500 mM ACS2 peptide using MS. Error bars: SE of
linear fits to time series experiments.
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Sirt3 Inhibition by 40-Bromo-ResveratrolThe 40-Bromo-Resveratrol Inhibition Behavior Depends
on the Peptide Substrate
The surface pocket accommodating 40-bromo-resveratrol in the
hSirt3/ACS2 complex would be allosteric and should act equally
on different substrate peptides, while the internal 40-bromo-
resveratrol site of the complex with hSirt3/FdL-1 should lead to
competition with ACS2 peptide, but not with the C-terminally
shorter FdL-1 substrate. To analyze the relevance of the two
identified 40-bromo-resveratrol binding sites for inhibition, we
therefore performed competition analyses.
To test for competition between 4’-bromo-resveratrol and
FdL-1 peptide, IC50 values for 4
0-bromo-resveratrol inhibition
of hSirt3 were determined at three different concentrations of
FdL-1 peptide (50, 100, and 200 mM). The IC50 values obtained
were 100 mM for all three peptide concentrations (Figure 4A),
indicating that the inhibitor 40-bromo-resveratrol does not
compete against FdL-1.
To test for 40-bromo-resveratrol competition with ACS2
peptide, MS assays were performed to determine Km and
Vmax values for the peptide at different compound concentra-Chemistry & Biology 20, 1375–1385, November 21, 2013 ªtions. The result shows that the higher
the 40-bromo-resveratrol concentration,
the more the Km for substrate peptideincreases, or apparent affinity for substrate decreases, while
the Vmax is not altered, indicating competitive inhibition with
respect to the peptide substrate (Figure 4B; Figure S3).
This competition was confirmed through binding measure-
ments. ACS2 peptide bound to apo hSirt3 with a Kd value
of 64.4 ± 9.1 mM. In presence of 50 mM 40-bromo-resveratrol,
the Kd value increased to more than 200 mM (Figure 4C).
Consistently, binding affinity of 40-bromo-resveratrol to the
apo protein was 7.6 ± 0.9 mM, and the Kd increased to higher
than 37 mM in the presence of 500 mM ACS2 peptide (Fig-
ure 4D). Thus, 40-bromo-resveratrol inhibits hSirt3 through
competition with ACS2 peptide substrate. The Ki of 4
0-
bromo-resveratrol calculated from the IC50 based on peptide
competition is 8 mM, in good agreement with the measured
binding affinity.
Our competition experiments with FdL-1 and ACS2 peptide
indicate that hSirt3 inhibition is due to 40-bromo-resveratrol
binding to the internal site, which causes competition with the
C-terminally longer ACS2 peptide and which would also lead
to competition with NAD+. We therefore also tested for2013 Elsevier Ltd All rights reserved 1379
Figure 4. The 40-Bromo-Resveratrol Inhibi-
tion Behavior Depends on the Peptide Sub-
strate
(A) IC50 determination for 4
0-bromo-resveratrol
inhibition of hSirt3 at 50, 100, and 200 mM FdL-1
substrate peptide.
(B) 40-Bromo-resveratrol inhibition of hSirt3 with
ACS2peptideasasubstrate. 40-Bromo-resveratrol
concentrations of 0, 50, and 150 mM resulted in Km
values for substrate peptide of 31.3 ± 9.0, 48.6 ±
7.5, and 253.3 ± 52.9 mM, respectively, while the
Vmax is roughly constant at 50 nmol mg1 min1.
Error bars: SE of linear fits to time series experi-
ments. See Figure S3 for Lineweaver-Burk plots.
(C) Binding affinity of ACS2 peptide to hSirt3 in
the presence or absence of 50 mM 40-bromo-
resveratrol.
(D)Bindingaffinity of 40-bromo-resveratrol to hSirt3
in the presence or absence of 500 mM ACS2 pep-
tide.
(E) 40-bromo-resveratrol inhibition of hSirt3 activity
against ACS2 peptide at varying NAD+ concen-
trations. 40-Bromo-resveratrol concentrations of
0 and 150 mM resulted in Km values for the co-
substrate NAD+ of 264.7 ± 53.4 and 753.6 ± 49.0,
respectively, while the Vmax is roughly constant at
50nmolmg1min1. Errorbars:SEof linear fits to
time series experiments.
(F) Lineweaver-Burk plot of the data for 40-bromo-
resveratrol inhibition of hSirt3 at varying NAD+
concentrations shown in (E).
(G) Binding affinity of 4’-bromo-resveratrol to
hSirt3 in the presence or absence of 2 mM NAD+.
The samedata for apohSirt3 as in (D) is included for
comparison.
(H) Binding of 40-bromo-resveratrol to hSirt3 in the
presence or absence of 10 mM or 40 mM nicotin-
amide, respectively. Absolute values are plotted
due to the lack of reliable upper baseline values for
normalization.
(A, C, D, G, and H) Error bars: SD from two inde-
pendent measurements.
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Sirt3 Inhibition by 40-Bromo-Resveratrolcompetition between the cosubstrate and compound in hSirt3
binding and activity assays. Adding inhibitor to hSirt3 activity
assays strongly increased the Km for NAD
+ without affecting
the Vmax (Figures 4E and 4F), indicating competitive inhibition
with respect to the cosubstrate. The binding affinity of 40-
bromo-resveratrol to the apo protein was 7.6 ± 0.9 mM, and
the Kd increased to higher than 50 mM when measured in pres-
ence of 2 mM NAD+ (Figure 4G), confirming competitive binding1380 Chemistry & Biology 20, 1375–1385, November 21, 2013 ª2013 Elsevier Ltd All rights reof inhibitor and cosubstrate. We further
tested 40-bromo-resveratrol binding in
presence and absence of nicotinamide,
which corresponds to the cosubstrate
moiety that occupies the C-pocket of
the NAD+ binding site. This pocket also
accommodates the A-ring of 40-bromo-
resveratrol in the internal site, and we
indeed observed a weaker inhibitor affin-
ity in presence of nicotinamide (Fig-
ure 4H) indicating competition for thissite. These results show that 40-bromo-resveratrol also com-
petes with NAD+, and in particular with its nicotinamide moiety,
for binding to hSirt3, confirming that the internal 40-bromo-
resveratrol binding site is the one relevant for hSirt3 inhibition.
Based on an NAD+ competitive inhibition mechanism, the Ki
for 40-bromo-resveratrol calculated from the IC50 value is
18 mM, in the range but slightly higher than expected from
the compound’s binding affinity.served
Figure 5. Analysis of the 40-Bromo-Resver-
atrol Binding Sites through Comparison to
other Sirtuin Structures
(A) Superposition of the hSirt3/FdL-1/40-bromo-
resveratrol complex with a Sir2Tm/p53/nicotin-
amide complex (PDB ID 1YC5; Avalos et al., 2005).
Dashed lines indicate hydrogen bonds of the
40-bromo-resveratrol A-ring hydroxyl groups and
of the nicotinamide carboxamide group to protein
residues. 40-Bromo-resveratrol is shown in pink
and nicotinamide in yellow. The protein part of the
Sir2Tm/p53/nicotinamide complex is omitted for
clarity. Sir2Tm residues are labeled with a star.
(B) Superposition of the hSirt3/FdL-1/40-bromo-
resveratrol complex with a hSirt1/NAD+/Ex-527
complex (PDB ID 4I5I; Zhao, et al., 2013).
40-Bromo-resveratrol (pink) and Ex-527 (green)
both occupy the C site but extend in different
directions.
(C) Superposition of the hSirt3/ACS2/40-bromo-
resveratrol complex (cyan) with a homology model
of hSirt1 (orange). 40-Bromo-resveratrol of hSirt3
is close to the putative position of Glu230 (magenta) of hSirt1 suggesting the involvement of the compound binding site to an allosteric hSirt1 activation
mechanism. hSirt1 N and C termini and Glu230 are labeled with a star. A missing hSirt3 loop is indicated by a dashed line. See Figure S4C for a crystal contact
blocking this site in the hSirt3/FdL-1/40-bromo-resveratrol complex.
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of resveratrol to a bromine atom dramatically changes the effect
on Sirtuins, and our structural data reveal the internal binding site
exploited by this compound for potent Sirtuin inhibition.
DISCUSSION
Resveratrol was reported to activate hSirt1 and several of its or-
thologs (Howitz et al., 2003). Many studies on finding the activa-
tion mechanism failed (Moniot et al., 2012) and in particular, a
hSirt1/resveratrol complex structure is lacking. Resveratrol
also inhibits hSirt3, and we used the 40-bromo reveratrol deriva-
tive to study its action on hSirt3. 40-Bromo-resveratrol turned out
to be a more potent hSirt3 inhibitor than resveratrol itself or its
derivatives piceatannol and polydatin. A previous crystal struc-
ture of a hSirt3/FdL-1/piceatannol complex revealed an exposed
binding site and a direct interaction between compound and
FdL-1 fluorophore, which explained the influence of this fluoro-
phore on compound effects (Borra et al., 2005; Gertz et al.,
2012; Kaeberlein et al., 2005; Pacholec et al., 2010). However,
the hSirt3/FdL-1/piceatannol complex would not easily explain
the increased potency of a 40-bromo derivative and the inhibition
rather than activation of hSirt1, and we indeed find that
40-bromo-resveratrol binds to a different site and does not con-
tact the FdL-1 fluorophore. Binding of 40-bromo-resveratrol to
this ligand site (see below) is surprising considering the com-
pound’s very small structural difference to resveratrol and picea-
tannol. Our biochemical data confirm that 40-bromo-resveratrol
inhibits through binding to this internal site, and the compound
thus defines an additional class of Sirtuin modulators, related
to resveratrol in chemical structure but acting through a distinct-
Sirtuin binding mode. Although 40-bromo-resveratrol is an order
of magnitude more potent than resveratrol (Gertz et al., 2012;
Milne et al., 2007), potency and selectivity need to be improved
either by modifying the compound or by identifying novel ligands
for this site. Our structural data can support both approaches byChemistry & Biology 20, 1375–138providing a template for docking searches for new ligands and
by suggesting modifications to 40-bromo-resveratrol that might
improve binding and selectivity. 40-Bromo-resveratrol partially
occupies the C pocket, where NAD+ binds in its productive
conformation with its nicotinamide moiety to initialize the reac-
tion andwhere nicotinamide can bind to an alkylimidate complex
(Sauve et al., 2006) for the reverse reaction (Figure 5A). A hydrox-
yl group of the 40-bromo-resveratrol A-ring plays a role like the
nicotinamide carboxamide group, which also interacts with the
conserved Asp101 (Asp231 in hSirt3) in a Sir2Tm/nicotinamide
complex (Avalos et al., 2005). The C-site is also exploited by
Ex-527 (Gertz et al., 2013; Zhao et al., 2013), a potent hSirt1 in-
hibitor (Napper et al., 2005; Solomon et al., 2006). However, 40-
bromo-resveratrol and Ex-527 extend from the C-pocket in
different directions (Figure 5B). While the kinked Ex-527 mole-
cule extends perpendicular to its carbamide in a hydrophobic
pocket close to the acetyl-Lys binding site, 40-bromo-resveratrol
extends with its B-ring toward a pocket close to the enzyme’s
surface. Similarily, the recently characterized hSirt3 binding
modes of SRT1720 and of thieno[3,2-d]pyrimidine-6-carboxa-
mides (Disch et al., 2013; Nguyen et al., 2013) show some over-
lap with 40-bromo-resveratrol, but do not extend in the B-ring
pocket (Figure S4A). The bromo-containing B-ring appears to
show some rotational flexibility within this hydrophobic binding
cleft, indicated by weak omit Fo-Fc density. However, the
bromine anchors it through mainly hydrophobic interactions, ex-
plaining why 40-bromo-resveratrol efficiently occupies this
pocket for potent inhibition while the more polar resveratrol
and piceatannol do not show significant affinity for this site. Add-
ing a longer, hydrophilic group inmeta position to the bromine for
interaction with Glu198 might strengthen binding and thus in-
crease potency. In Sirt5, the pocket entrance is tightened (Fig-
ure S4B) and more polar due to the Sirt5-specific Arg105
(Fischer et al., 2012), explaining Sirt50s insensitivity to 40-
bromo-resveratrol and suggesting that replacing the B-ring
with a small polar group might enable to selectively target this5, November 21, 2013 ª2013 Elsevier Ltd All rights reserved 1381
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compared to hSirt3 (Figure S4B), so that B-ring modifications
should favor hSirt3 binding while B-ring replacements with
smaller hydrophobic groups should lead to preferential hSirt1
binding. Our complex structure thus reveals a target site for
Sirtuin inhibition, with 40-bromo-resveratrol as a prototype inhib-
itor exploiting this pocket, and our results and analyses indicate
potential and suggest strategies for using the compound and
binding site as starting points for the development of improved
Sirtuin inhibitors.
40-Bromo-resveratrol shows the same inhibitory effect on
hSirt1 as on hSirt3, and a similar internal binding pocket is pre-
sent in hSirt1 (see above), strongly suggesting that hSirt1 inhibi-
tion is based on the same binding site and competitive mecha-
nism. Interestingly, this competition excludes the inhibitory
40-bromo-resveratrol site as the binding pocket for the almost
identical, hSirt1 activating compound resveratrol, which consti-
tutes a remarkable switch in binding sites through a very small
difference in compound structure. The weak 40-bromo-resvera-
trol interaction site at the bottom of the Rossmann-fold domain
(its affinity has to be equal to or lower than the compound affinity
measured under ACS2 peptide saturation, KdR 37 mM), howev-
er, might hint at an allosteric hSirt1 site for resveratrol binding. A
hSirt1model, based on its catalytic domain structure (Zhao et al.,
2013) and an N-terminally longer hSirt2 structure (Moniot et al.,
2013), indicates an extended conformation for an N-terminal
extension (residues 210–240) implicated in activation (Milne
et al., 2007; Figure 5C), consistent with H/D exchange data (Hub-
bard et al., 2013). Superposition with hSirt3/ACS2/40-bromo-
resveratrol indicates that the extension could contribute to the
external 40-bromo-resveratrol binding site. In particular, hSirt1-
Glu230, a residue essential for activation (Hubbard et al.,
2013), is located next to this binding site (Figure 5C), and we
thus speculate that it might serve as allosteric activation site in
hSirt1. It is connected to substrate binding loops (324–330 and
292–299, hSirt3 numbering) through a11 and a10 (Figure 5C),
and a coupling of these sites would provide a molecular activa-
tion model explaining the substrate sequence influence on com-
pound effects (Lakshminarasimhan et al., 2013a). A recent yeast
Sir2 structure (Hsu et al., 2013) revealed binding of the activator
protein Sir4 between a10/11 and an N-terminal regulatory
domain of Sir2 positioned similar to the Sirt1 extension, support-
ing such an allosteric activation mechanism, but definite conclu-
sions on the mechanism of hSirt1 activation will require further
studies on this protein. A superposition of hSirt3/ACS2/40-
bromo-resveratrol and hSirt3/FdL-1/40-bromo-resveratrol re-
veals that in the FdL-1 complex, a loop of a symmetry-related
monomer prevents binding to this allosteric site (Figure S4C).
This difference in crystal packing explains why this site was
not occupied in our FdL-1 complex structure in addition to the in-
ternal binding site responsible for potent hSirt1/3 inhibition.
SIGNIFICANCE
Sirtuins have been implicated in aging-related diseases and
are considered attractive drug targets. Extensive research
efforts aim to identify potent and specific Sirtuin inhibitor
for in vivo studies and therapy. HumanSirt1 and its orthologs
can also be activated by small molecules such as resvera-1382 Chemistry & Biology 20, 1375–1385, November 21, 2013 ª2013trol, and the resulting beneficial health effects have spurred
research onSirtuin activators. The development of improved
Sirtuin inhibitors and activators has been hampered, howev-
er, by the lack of knowledge on binding sites andmodulation
mechanisms of available compounds. We studied Sirtuin
modulation by using 40-bromo-resveratrol, a derivative of
the weak Sirt1 activator and weak Sirt3 inhibitor resveratrol
that can be identified unequivocally in crystal structures.
The compound inhibited Sirt3 with much higher potency
than resveratrol, and it also inhibited rather than activated
Sirt1. Crystal structures of human Sirt3/peptide complexes
in presence of 40-bromo-resveratrol identified two com-
pound binding sites. An internal site, overlapping with the
active site, causes the potent inhibitory effect. The com-
pound interferes with NAD+ and substrate peptide binding,
and it extends its bromo-phenyl group in a so far not recog-
nized hydrophobic active site pocket. These results identify
a different type of Sirtuin inhibitor and an additional Sirtuin
site that can be targeted for inhibitor development. The sec-
ond binding site for 40-bromo-resveratrol is located on the
surface of Sirt3 and connected through two helices to pep-
tide-binding active site loops. In Sirt1, this site appears to
comprise a residue that is essential for its activation by small
molecules and it therefore constitutes a candidate for the
long-sought allosteric Sirt1 activator binding site. Our study
thus provides insights into binding sites and mechanisms
for Sirtuin regulation, supporting the development of
improved Sirtuin-targeting drugs.
EXPERIMENTAL PROCEDURES
Chemicals and Peptides
Chemicals were from Sigma if not stated otherwise. 5-(2-(4-hydroxyphenyl)vi-
nyl)-1,3-benzenediol was from Matrix Scientific. ACS2 peptide (TRSGace-
tylKVMRRL) was synthesized and HPLC purified by GL Biochem, FdL-1
peptide was from Enzo Life Sciences.
Cloning, Protein Expression, and Purification
hSirt1, hSirt3, and hSirt5 were cloned, expressed, and purified as described in
previous reports (Gertz et al., 2012; Lakshminarasimhan et al., 2013b). Briefly,
full-length hSirt1 (in vector pET15b coding for an N-terminal His-tag; Life Tech-
nologies) and the catalytic core domains of hSirt3 (residues 118–399, in vector
pVFT3S [Sungkyunkwan University, South Korea] coding for an N-terminal
His-Trx-tag) and hSirt5 (residues 34–302 in vector pET151/D-TOPO coding
an N-terminal His-tag) were expressed in Escherichia coli strain BL21DE3
Rosetta2 (Merck, Whitehouse Station, NJ) at 15C upon induction with
0.5 mM isopropyl-b-D-thiogalactoside. The fusion proteins were purified by
affinity chromatographywith talon resin. TheHis-Trx-tag of hSirt3was removed
by addition of Tobacco Etch Virus (TEV) protease. The tag-cleaved hSirt3
was resubjected to talon chromatography to remove tag and protease. Finally,
hSirt1, hSirt3, and hSirt5 were subjected to Superose-12 gel filtration chroma-
tography (GE Healthcare), and the purified proteins were shock-frozen and
stored at 80C.
Crystallization and Structure Solution
hSirt3 (8 mg/ml in 20 mM Tris/HCl, pH 7.8, and 150 mM NaCl) was crystallized
in complex with FdL-1 or ACS2 peptide and 40-bromo-resveratrol after pre-in-
cubation with 2mMpeptide and 1mMcompound (10% [v/v] DMSO) for 1 hr on
ice. Protein solution was mixed with reservoir (hSirt3/FdL-1/40-bromo-resver-
atrol, 200 mM NaCl, 100 mM HEPES pH 7, 10% [v/v] isopropanol; hSirt3/
ACS2/40-bromo-resveratrol, 250 mM [NH4]2SO4, 100 mM BisTris pH 6, 21%
[w/v] PEG 3350) in a 1:1 ratio and equilibrated against 0.4 ml reservoir at
20C. The crystals were transferred to cryo solution containing reservoir,Elsevier Ltd All rights reserved
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nitrogen.
The X-ray diffraction data were collected at 100 K with an MX-225 CCD de-
tector (Rayonix) at beam lineMX14.1 of the BESSY II electron storage ring (Mu-
eller et al., 2012). The wavelength was 0.92 A˚, allowing observation of the
anomalous diffraction of the Br atom. Diffraction data were processed using
XDS (Kabsch, 2010). Crystal structures were solved by Patterson searches
with the program MolRep (Vagin and Isupov, 2001) using the protein part of
the hSirt3/FdL-1/PCT complex (Protein Data Bank [PDB] ID 4HD8; Gertz
et al., 2012) as a search model. Structure refinement was performed using
Refmac (Murshudov et al., 1997), and manual rebuilding was done in Coot
(Emsley and Cowtan, 2004). Parameter files for 40-bromo-resveratrol were
generated using ProDrg (Schu¨ttelkopf and van Aalten, 2004). The quality of
the refined structures was evaluated by using Coot and MolProbity (Chen
et al., 2010).
The FdL-1 fluorophore in the complex hSirt3/FdL-1/40-bromo-resveratrol
was modeled as the commonly used 7-amino-4-methylcoumarin ring (Gertz
et al., 2012). A small blob of additional electron density at the methyl group
of the fluorophore might indicate that a slightly different group is attached to
the coumarin, and we indeed find a difference (43 Da) between calculated
and measured FdL-1 mass (data not shown). However, no fluorophore details
are available from the manufacturer (Enzo Life Sciences), and the mass differ-
ence would also be explained by the common acetylation of the peptide’s N
terminus. We therefore kept the 7-amino-4-methylcoumarin as fluorophore
in our FdL-1 model.
Homology Modeling of N-Terminally Extended hSirt1
A homology model for hSirt1 (UniProt entry Q96EB6) residues 210–516 was
generated using the published hSirt1 catalytic core crystal structure (residues
241–516; PDB ID 4I5I; Zhao et al., 2013) and a re-refined crystal structure of
hSirt2 residues 34–356 (PDB ID 3ZGO; Moniot et al., 2013) as templates. A
structure-based alignment of the template sequences was generated with
STRAP (Gille and Fro¨mmel, 2001) and the extended hSirt1 sequence added
manually. The hSirt1 model was generated from this alignment by using
Modeler version 9.10 (Sali and Blundell, 1993).
Deacetylation Assays
The deacylase activities of hSirt1, hSirt3, and hSirt5 were tested using a com-
mercial Fluor-de-lys assay kit (Enzo Life Sciences) containing acetylated
(hSirt1, hSirt3) or succinylated (hSirt5) FdL-substrate peptides with a C-termi-
nally attached fluorophore. Onemicrogram of hSirt1 was incubated with 25 mM
FdL-1 and 50 mMNAD+, 1.5 mg hSirt3 with 0.1 mM FdL-1 and 2.5 mMNAD+, or
0.5 mg hSirt5 with 0.1 mM FdL-Succinyl Green and 2.5 mM NAD+ in the pres-
ence of 0.2 mM or 1 mM compound and 2% (v/v) DMSO, or with 2% (v/v)
DMSO without compound as a control, for 30 min at 37C. The mixture was
then incubated with the trypsin developer for 45 min at room temperature to
release the fluorophore from deacetylated FdL-1. Fluorescence was deter-
mined at excitation wavelengths of 360 nm (acetyl-FdL-1) and 486 nm
(FdL-Succinyl Green), respectively, and emission wavelengths of 460 nm
(acetyl-FdL-1) and 530 nm (FdL-Succinyl Green).
For the MS assay, 10 mM hSirt3 was incubated with 0.5 mM ACS2 peptide
and 2.5 mM NAD+ (or the indicated concentrations in titration experiments)
in the presence or absence of different 40-bromo-resveratrol concentrations
in 2% (v/v) DMSO, or with 2% (v/v) DMSO without compound as a control,
at 37C. The reaction was stopped after different time points by adding
0.25% (v/v) trifluoroacetic acid followed by dilution to 1 mM peptide in 0.1%
(v/v) formic acid. Finally, the solution was filtered to separate ACS2 peptide
from the reaction mixture and subjected to nano-LC-MS/MS analysis as
described previously (Fischer et al., 2012). Specific deacetylation activity
was determined by linear fitting of the time-series experiments.
Binding Analysis by Microscale Thermophoresis
Binding affinities were measured by microscale thermophoresis (Wienken
et al., 2010) with 1 mM hSirt3 in 20 mM Tris pH 7.8, and 150 mM NaCl in the
presence or absence of competitor and the indicated 40-bromo-resveratrol
or ACS2 peptide concentrations. Protein and ligands were mixed and trans-
ferred into glass capillaries at room temperature, and thermophoresis was
analyzed at 25C using a NanoTemper Monolith NT.label-free instrumentChemistry & Biology 20, 1375–138(NanoTemper Technologies, Mu¨nchen, Germany) and the intrinsic protein
fluorescence signal (excitation at 280 nm, emission at 360 nm). The excitation
LED power was set to 25%, and the IR-laser power to 20%–80%. Affinities
were determined through non-linear fitting (1-site equation) of the measured
thermophoresis values using Prism (GraphPad Software, La Jolla, CA), and
signals are presented normalized to the signal difference between baselines
if saturation could be reached. Each experiment was repeated at least twice.
Statistical Analysis
Error bars for the MS activity assay represent SEs of linear regression analysis
of time series experiments with four data points. For FdL activity data and
binding measurements, error bars represent SDs from two independent
measurements.
ACCESSION NUMBERS
The PDB accession numbers for the coordinates and structure factors for the
crystal structures of hSirt3 in complex with peptide and 5-(2-(4-bromophenyl)
vinyl)-1,3-benzenediol are 4C7B (FdL-1 peptide complex) and 4C78 (ACS2
peptide complex).
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